{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:11:29Z","timestamp":1791882689249,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program, National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA054543"],"award-info":[{"award-number":["R01DA054543"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-acting injectable PrEP was approved for use in the US in 2021 but roll out has been slow, with few studies exploring uptake among cisgender women who inject drugs (WWID). We purposively recruited 25 WWID within 30-days of receiving a PrEP prescription from a low-barrier clinic co-located with a syringe services program to complete semi-structured interviews about PrEP product choice. We used an intersectional lens to compare decision-making between women choosing injectable PrEP versus oral PrEP and continued enrolling new participants until we reached thematic saturation (12\/2022 to 2\/2024). Participants represent a diverse sample of WWID (12 women of color) with median age 43 years. Daily injection drug use (72%) and \u2265\u20091 sex partner (64%) were common. Salient themes from interviews include: (1) PrEP provides women with a valued safety net and initiation is a form of self-preservation. (2) Co-located care, small incentives, and provider respect for WWID's medical autonomy helped participants navigate a multi-visit PrEP intake process. (3) Longer lasting HIV protection with less frequent dosing is preferrable to a shorter acting daily oral medication. When selecting a product, WWID evaluated its attributes against their medical history and personal circumstances like homelessness (64%). Most chose CAB-LA (72%) because it provides longer lasting protection which was a highly valued product attribute. Together, our findings underscore the critical importance of offering multiple PrEP options when implementing HIV prevention strategies that are patient-centered and responsive to the unique needs of WWID.<\/jats:p>","DOI":"10.1007\/s10461-025-04833-5","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:15:45Z","timestamp":1754475345000},"page":"3970-3980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u201cThe Simplest Way to Go\u201d: An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP"],"prefix":"10.1007","volume":"29","author":[{"given":"Alexis M.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rivet","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Krakower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Mazzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam W.","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"5","key":"4833_CR1","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s10461-019-02733-z","volume":"24","author":"JL Glick","year":"2020","unstructured":"Glick JL, Russo R, Jivapong B, Rosman L, Pelaez D, Footer KHA, et al. The PrEP Care Continuum Among Cisgender Women Who Sell Sex and\/or Use Drugs Globally: A Systematic Review. AIDS Behav. 2020;24(5):1312\u201333. https:\/\/doi.org\/10.1007\/s10461-019-02733-z. PubMed PMID: 31807973; PubMed Central PMCID: PMCPMC7899785.","journal-title":"AIDS Behav"},{"issue":"5","key":"4833_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","volume":"25","author":"CB Mistler","year":"2021","unstructured":"Mistler CB, Copenhaver MM, Shrestha R. The Pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: A systematic review. AIDS Behav. 2021;25(5):1490\u2013506. https:\/\/doi.org\/10.1007\/s10461-020-02988-x. PubMed PMID: 32749627; PubMed Central PMCID: PMCPMC7858689.","journal-title":"AIDS Behav"},{"issue":"1\u20132","key":"4833_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2011.12.020","volume":"124","author":"DC Des Jarlais","year":"2012","unstructured":"Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high Seroprevalence areas. Drug Alcohol Depend. 2012;124(1\u20132):95\u2013107 PubMed PMID: 22257753; PubMed Central PMCID: PMCPMC3353009.","journal-title":"Drug Alcohol Depend"},{"key":"4833_CR4","unstructured":"U.S. Centers for Disease Control and Prevention. HIV Surveillance Special Report: HIV Infection Risk, Prevention, and Testing Behaviors Among Persons Who Inject Drugs National HIV Behavioral Surveillance, 20, Cities US. 2022 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/150464"},{"issue":"1","key":"4833_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","volume":"76","author":"H Bradley","year":"2023","unstructured":"Bradley H, Hall EW, Asher A, Furukawa NW, Jones CM, Shealey J, et al. Estimated number of people who inject drugs in the united States. Clin Infect Dis. 2023;76(1):96\u2013102. https:\/\/doi.org\/10.1093\/cid\/ciac543. Epub 2022\/07\/07.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4833_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/10826084.2017.1404105","volume":"53","author":"MD Morris","year":"2018","unstructured":"Morris MD, Montgomery ME, Briceno A, Evans JL, Andrew EVW, Page K, et al. A study of sexual relationship power among young women who inject drugs and their sexual partners. Subst Use Misuse. 2018;53(8):1281\u20137. https:\/\/doi.org\/10.1080\/10826084.2017.1404105.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"4833_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12954-025-01204-0","volume":"22","author":"\u00c1R Banze","year":"2025","unstructured":"Banze \u00c1R, Bot\u00e3o C, Muamine E, Condula M, Craveirinha S, Boothe M, et al. Understanding HIV vulnerability among women who inject drugs in Mozambique, 2023. Harm Reduct J. 2025;22(1):61\u20138. https:\/\/doi.org\/10.1186\/s12954-025-01204-0.","journal-title":"Harm Reduct J."},{"key":"4833_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.puhe.2023.09.024","volume":"225","author":"E Emanuel","year":"2023","unstructured":"Emanuel E, Slater L, Croxford S, Edmundson C, Ibitoye A, Njoroge J, et al. Adverse health outcomes among people who inject drugs who engaged in recent sex work: findings from a National survey. Public Health (London). 2023;225:79\u201386. https:\/\/doi.org\/10.1016\/j.puhe.2023.09.024.","journal-title":"Public Health (London)"},{"issue":"3","key":"4833_CR9","doi-asserted-by":"publisher","first-page":"e0230886","DOI":"10.1371\/journal.pone.0230886","volume":"15","author":"J Valencia","year":"2020","unstructured":"Valencia J, Alvaro-Meca A, Troya J, Guti\u00e9rrez J, Ram\u00f3n C, Rodr\u00edguez A, et al. Gender-based vulnerability in women who inject drugs in a harm reduction setting. PLoS ONE. 2020;15(3):e0230886. https:\/\/doi.org\/10.1371\/journal.pone.0230886. Epub 20200330. PubMed PMID: 32226042; PubMed Central PMCID: PMCPMC7105126.","journal-title":"PLoS ONE"},{"issue":"4","key":"4833_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/08897077.2020.1865242","volume":"42","author":"JK Stockman","year":"2021","unstructured":"Stockman JK, Syvertsen JL, Hayashi HD, Ludwig-Barron N, Tsuyuki K, Morris MD, et al. Violence and love and drugs...it all goes hand in hand: a mixed methods analysis of the substance abuse, violence, and HIV\/AIDS syndemic among women who use methamphetamine. Subst Abus. 2021;42(4):821\u201331. https:\/\/doi.org\/10.1080\/08897077.2020.1865242. Epub 20210125. PubMed PMID: 33492198; PubMed Central PMCID: PMCPMC8442613.","journal-title":"Subst Abus."},{"issue":"S1","key":"4833_CR11","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1111\/dar.12631","volume":"37","author":"H Reddon","year":"2018","unstructured":"Reddon H, Pettes T, Wood E, Nosova E, Milloy M-J, Kerr T, et al. Incidence and predictors of mental health disorder diagnoses among people who inject drugs in a Canadian setting. Drug Alcohol Rev. 2018;37(S1):S285\u201393. https:\/\/doi.org\/10.1111\/dar.12631.","journal-title":"Drug Alcohol Rev"},{"key":"4833_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2018.06.009","volume":"190","author":"C Couto e Cruz","year":"2018","unstructured":"Couto e Cruz C, Salom CL, Dietze P, Lenton S, Burns L, Alati R. Frequent experience of discrimination among people who inject drugs: links with health and wellbeing. Drug Alcohol Depend. 2018;190:188\u201394. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.009.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"4833_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12888-023-05008-z","volume":"23","author":"HT Saleem","year":"2023","unstructured":"Saleem HT, West NS, Likindikoki S. Prevalence and predictors of depressive and anxiety symptoms in a sample of women who use drugs in tanzania: the key role of drug use stigma. BMC Psychiatry. 2023;23(1):517. https:\/\/doi.org\/10.1186\/s12888-023-05008-z.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"4833_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1186\/s12889-019-7557-8","volume":"19","author":"M Chen","year":"2019","unstructured":"Chen M, Ma Y, Chen H, Dai J, Luo H, Yang C, et al. Demographic characteristics and Spatial clusters of recent HIV-1 infections among newly diagnosed HIV-1 cases in yunnan, china, 2015. BMC Public Health. 2019;19(1):1507. https:\/\/doi.org\/10.1186\/s12889-019-7557-8.","journal-title":"BMC Public Health"},{"issue":"5","key":"4833_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11524-017-0179-5","volume":"94","author":"P Marotta","year":"2017","unstructured":"Marotta P. Assessing Spatial relationships between race, inequality, crime, and gonorrhea and Chlamydia in the united States. J Urb Health. 2017;94(5):683\u201398. https:\/\/doi.org\/10.1007\/s11524-017-0179-5.","journal-title":"J Urb Health"},{"issue":"1","key":"4833_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1353\/hpu.2018.0026","volume":"29","author":"BO Ojikutu","year":"2018","unstructured":"Ojikutu BO, Bogart LM, Klein DJ, Galvan FH, Wagner GJ. Neighborhood crime and sexual transmission risk behavior among black men living with HIV. J Health Care Poor Underserved. 2018;29(1):383\u201399. https:\/\/doi.org\/10.1353\/hpu.2018.0026.","journal-title":"J Health Care Poor Underserved"},{"issue":"11","key":"4833_CR17","doi-asserted-by":"publisher","first-page":"e2024577","DOI":"10.1001\/jamanetworkopen.2020.24577","volume":"3","author":"FM Momplaisir","year":"2020","unstructured":"Momplaisir FM, Nassau T, Moore K, Grayhack C, Njoroge WFM, Diez Roux AV, et al. Association of adverse neighborhood exposures with HIV viral load in pregnant women at delivery. JAMA Netw Open. 2020;3(11):e2024577\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.24577.","journal-title":"JAMA Netw Open"},{"key":"4833_CR18","doi-asserted-by":"publisher","first-page":"951682","DOI":"10.3389\/fpsyt.2022.951682","volume":"13","author":"D Guy","year":"2022","unstructured":"Guy D, Doran J, White TM, van Selm L, Noori T, Lazarus JV. The HIV pre-exposure prophylaxis continuum of care among women who inject drugs: A systematic review. Front Psychiatry. 2022;13:951682. https:\/\/doi.org\/10.3389\/fpsyt.2022.951682. Epub 20220826. PubMed PMID: 36090369; PubMed Central PMCID: PMCPMC9459118.","journal-title":"Front Psychiatry"},{"issue":"2","key":"4833_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/apc.2014.0142","volume":"29","author":"JD Auerbach","year":"2014","unstructured":"Auerbach JD, Kinsky S, Brown G. Knowledge, attitudes, and likelihood of Pre-Exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2014;29(2):102\u201310. https:\/\/doi.org\/10.1089\/apc.2014.0142.","journal-title":"AIDS Patient Care STDs"},{"issue":"01","key":"4833_CR20","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1097\/qai.0000000000000659","volume":"69 Suppl 2","author":"J Iversen","year":"2015","unstructured":"Iversen J, Page K, Madden A, Maher L. HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment. J Acquir Immune Defic Syndr. 2015;69 Suppl 2(01):S176-81. https:\/\/doi.org\/10.1097\/qai.0000000000000659. Epub 2015\/05\/16. PubMed PMID: 25978485; PubMed Central PMCID: PMCPMC4505917.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"5","key":"4833_CR21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10461-021-03495-3","volume":"26","author":"SK Calabrese","year":"2022","unstructured":"Calabrese SK, Kalwicz DA, Modrakovic D, Earnshaw VA, Edelman EJ, Bunting SR, et al. An experimental study of the effects of patient race, sexual orientation, and injection drug use on providers\u2019 PrEP-Related clinical judgments. AIDS Behav. 2022;26(5):1393\u2013421. https:\/\/doi.org\/10.1007\/s10461-021-03495-3. Epub 20211109. PubMed PMID: 34750695; PubMed Central PMCID: PMCPMC9434708.","journal-title":"AIDS Behav"},{"issue":"12","key":"4833_CR22","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1080\/10826084.2020.1788088","volume":"55","author":"L Owens","year":"2020","unstructured":"Owens L, Elizabeth M, Courtney M, Glick S. Reproductive health care utilization by women who inject drugs and exchange sex in the Seattle area. Subst Use Misuse. 2020;55(12):2020\u20134. https:\/\/doi.org\/10.1080\/10826084.2020.1788088.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"4833_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40352-021-00135-9","volume":"9","author":"A Hoadley","year":"2021","unstructured":"Hoadley A, Bass SB, Brujaha J, D\u2019Avanzo PA, Kelly PJ. Healthcare beliefs, health information seeking, and healthcare setting preferences among women who inject drugs by community supervision status. Health Justice. 2021;9(1):10. https:\/\/doi.org\/10.1186\/s40352-021-00135-9.","journal-title":"Health Justice"},{"key":"4833_CR24","volume-title":"X\u2019 they distrust: exploring institutional distrust as a determinant of healthcare engagement among women who use drugs amid the COVID-19 pandemic","author":"LN Sisson","year":"2024","unstructured":"Sisson LN. X\u2019 they distrust: exploring institutional distrust as a determinant of healthcare engagement among women who use drugs amid the COVID-19 pandemic. JScholarship: John Hopkins University; 2024."},{"issue":"2","key":"4833_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/08897077.2018.1544184","volume":"40","author":"JD Cockroft","year":"2019","unstructured":"Cockroft JD, Adams SM, Bonnet K, Matlock D, McMillan J, Schlundt D. A Scarlet letter: stigma and other factors affecting trust in the health care system for women seeking substance abuse treatment in a community setting. Subst Abuse. 2019;40(2):170\u20137. https:\/\/doi.org\/10.1080\/08897077.2018.1544184. PubMed PMID: 30759047.","journal-title":"Subst Abuse"},{"issue":"7","key":"4833_CR26","doi-asserted-by":"publisher","first-page":"e2221346","DOI":"10.1001\/jamanetworkopen.2022.21346","volume":"5","author":"CG Streed Jr","year":"2022","unstructured":"Streed CG Jr, Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL. Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use. JAMA Netw Open. 2022;5(7):e2221346\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.21346.","journal-title":"JAMA Netw Open"},{"key":"4833_CR27","doi-asserted-by":"publisher","first-page":"113809","DOI":"10.1016\/j.socscimed.2021.113809","volume":"275","author":"M Felsher","year":"2021","unstructured":"Felsher M, Ziegler E, Amico KR, Carrico A, Coleman J, Roth AM. PrEP just isn\u2019t my priority: adherence challenges among women who inject drugs participating in a pre-exposure prophylaxis (PrEP) demonstration project in philadelphia, PA USA. Soc Sci Med. 2021;275:113809. PubMed PMID: 33735778; PubMed Central PMCID: PMCPMC8009846.","journal-title":"Soc Sci Med"},{"issue":"7","key":"4833_CR28","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/s2352-3018(20)30106-5","volume":"7","author":"RJ Landovitz","year":"2020","unstructured":"Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472-81. https:\/\/doi.org\/10.1016\/s2352-3018(20)30106-5. Epub 20200601. PubMed PMID: 32497491; PubMed Central PMCID: PMCPMC7859863.","journal-title":"Lancet HIV"},{"issue":"7","key":"4833_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016. Epub 2021\/08\/12. PubMed PMID: 34379922; PubMed Central PMCID: PMCPMC8448593.","journal-title":"N Engl J Med"},{"issue":"10337","key":"4833_CR30","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/s0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389. https:\/\/doi.org\/10.1016\/s0140-6736(22)00538-4. Epub 20220401. PubMed PMID: 35378077; PubMed Central PMCID: PMCPMC9077443.","journal-title":"Lancet"},{"issue":"18","key":"4833_CR31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2024.21493","volume":"332","author":"LM Mann","year":"2024","unstructured":"Mann LM, Zhu W, Huang YA, Kourtis AP, Fanfair RN, Hoover KW. Trends in oral and injectable HIV preexposure prophylaxis prescriptions in the US, 2013\u20132023. JAMA. 2024;332(18):1580\u20133. https:\/\/doi.org\/10.1001\/jama.2024.21493. PubMed PMID: 39401236; PubMed Central PMCID: PMCPMC11581590.","journal-title":"JAMA"},{"key":"4833_CR32","unstructured":"Patel R. Why is cabotegravir rollout so slow? In: Conference on retroviruses and opportunistic infections; 2024; Denver, CO, USA."},{"issue":"10","key":"4833_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/09540121.2019.1587352","volume":"31","author":"KHA Footer","year":"2019","unstructured":"Footer KHA, Lim S, Rael CT, Greene GJ, Carballa-Di\u00e9guez A, Giguere R, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. City. AIDS Care. 2019;31(10):1207\u201313. https:\/\/doi.org\/10.1080\/09540121.2019.1587352.","journal-title":"AIDS Care"},{"issue":"7","key":"4833_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/apc.2022.0068","volume":"36","author":"AR Bazzi","year":"2022","unstructured":"Bazzi AR, Valasek CJ, Streuli SA, Vera CF, Harvey-Vera A, Philbin MM, et al. Long-Acting Injectable Human Immunodeficiency VirusPre-Exposure Prophylaxis Preferred Over Other Modalities Among People WhoInject Drugs: Findings from a Qualitative Study in California. AIDS Patient Care STDs. 2022;36(7):254\u201362. https:\/\/doi.org\/10.1089\/apc.2022.0068.","journal-title":"AIDS Patient Care STDs"},{"issue":"S2","key":"4833_CR35","doi-asserted-by":"publisher","first-page":"e26107","DOI":"10.1002\/jia2.26107","volume":"26","author":"L Lorenzetti","year":"2023","unstructured":"Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;26(S2):e26107. https:\/\/doi.org\/10.1002\/jia2.26107.","journal-title":"J Int AIDS Soc"},{"key":"4833_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae450","author":"AM Roth","year":"2024","unstructured":"Roth AM, Bartholomew TS, Ward KM, Groves A, Mazzella S, Bellamy S, et al. Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae450.","journal-title":"Clin Infect Dis"},{"key":"4833_CR37","unstructured":"Roth AM. Trauma intervention to optimize prep among women who inject Drugs (TIARAS). Clinical Trials Identifier: NCT05192434. 2023 [updated April 23 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05192434. Accessed May 1, 2025."},{"issue":"4","key":"4833_CR38","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907. https:\/\/doi.org\/10.1007\/s11135-017-0574-8.","journal-title":"Qual Quant"},{"key":"4833_CR39","doi-asserted-by":"publisher","DOI":"10.5771\/9780759123212","volume-title":"Rapid qualitative inquiry: a field guide to team-based assessment","author":"J Beebe","year":"2014","unstructured":"Beebe J. Rapid qualitative inquiry: a field guide to team-based assessment. Rowman & Littlefield; 2014."},{"issue":"8","key":"4833_CR40","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1007\/s10461-018-02387-3","volume":"23","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, Beima-Sofie K, Amico KR, Hosek SG, Johnson MO, Mensch BS. Debrief reports to expedite the impact of qualitative research: do they accurately capture data from In-depth interviews? AIDS Behav. 2019;23(8):2185\u20139. https:\/\/doi.org\/10.1007\/s10461-018-02387-3.","journal-title":"AIDS Behav"},{"issue":"6","key":"4833_CR41","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10508-020-01684-0","volume":"49","author":"M Felsher","year":"2020","unstructured":"Felsher M, Ziegler E, Smith LR, Sherman SG, Amico KR, Fox R, et al. An exploration of Pre-exposure prophylaxis (PrEP) initiation among women who inject drugs. Arch Sex Behav. 2020;49(6):2205\u201312. https:\/\/doi.org\/10.1007\/s10508-020-01684-0. Epub 20200409.","journal-title":"Arch Sex Behav"},{"key":"4833_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-025-04646-6","author":"LR Violette","year":"2025","unstructured":"Violette LR, Corcorran MA, Austin EJ, Williams EC, Glick SN, Dhanireddy S, et al. PrEP Awareness, Interest, and Use among Women Who Inject Drugs in Seattle, Washington: A Mixed Methods Study. AIDS Behav. 2025. https:\/\/doi.org\/10.1007\/s10461-025-04646-6.","journal-title":"AIDS Behav."},{"issue":"1","key":"4833_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12954-023-00729-6","volume":"20","author":"G Shaw","year":"2023","unstructured":"Shaw G, Schaefer R, Schmidt H-MA, Madden A, Chang J, Mozalevskis A, et al. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery. Harm Reduct J. 2023;20(1):16. https:\/\/doi.org\/10.1186\/s12954-023-00729-6.","journal-title":"Harm Reduct J"},{"key":"4833_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04598-3","author":"E Suarez","year":"2025","unstructured":"Suarez E, Tookes HE, Coppola M, Plesons M, Serota D, St. George SM, et al. Long-Acting Injectable Prep for People Who Inject Drugs at a Syringe Services Program: A Qualitative Acceptability and Feasibility Study. AIDS Behav. 2025. https:\/\/doi.org\/10.1007\/s10461-024-04598-3.","journal-title":"AIDS Behav"},{"issue":"1","key":"4833_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11904-024-00721-0","volume":"22","author":"MA Hatch","year":"2025","unstructured":"Hatch MA, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K, et al. HIV prevention in syringe service programs since the start of COVID-19: where do we go from here?? Curr HIV\/AIDS Rep. 2025;22(1):13. https:\/\/doi.org\/10.1007\/s11904-024-00721-0.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4833_CR46","unstructured":"Patel SV, Wenger LD, Humphrey JL, Saunders M, Strack C, Prohaska S et al. Inner and outer setting factors that impact syringe services programs\u2019 adoption and scale of key services for people who use drugs: Findings from the national survey of syringe services programs. 7th Biennial Conference for the Society for Implementation Research Collaboration; Denver, CO2024."},{"issue":"1","key":"4833_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12954-023-00861-3","volume":"20","author":"TS Bartholomew","year":"2023","unstructured":"Bartholomew TS, Tookes HE, Chueng TA, Bluthenthal RN, Wenger LD, Kral AH, et al. Availability of telehealth-based services at syringe services programs under the COVID-19 public health emergency. Harm Reduct J. 2023;20(1):122. https:\/\/doi.org\/10.1186\/s12954-023-00861-3.","journal-title":"Harm Reduct J"},{"issue":"1","key":"4833_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12889-020-8325-5","volume":"20","author":"J Pagkas-Bather","year":"2020","unstructured":"Pagkas-Bather J, Jaramillo J, Henry J, Grandberry V, Ramirez LF, Cervantes L, et al. What\u2019s prep?? Peer navigator acceptability among minority MSM in Washington. BMC Public Health. 2020;20(1):248. https:\/\/doi.org\/10.1186\/s12889-020-8325-5.","journal-title":"BMC Public Health"},{"issue":"2","key":"4833_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","volume":"1","author":"J Ross","year":"2013","unstructured":"Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982\u20132009. Global Health: Sci Pract. 2013;1(2):203. https:\/\/doi.org\/10.9745\/GHSP-D-13-00010.","journal-title":"Global Health: Sci Pract"},{"issue":"5","key":"4833_CR50","doi-asserted-by":"publisher","first-page":"e20210104","DOI":"10.1590\/0034-7167-2021-0104","volume":"75","author":"RRD Silva","year":"2022","unstructured":"Silva RRD, Silva Filho JAD, Lima ERD, Bel\u00e9m JM, Pereira RDS, Oliveira CAN. Woman-centered shared decision-making to promote contraceptive counseling: an integrative review. Revista Brasileira de Enfermagem. 2022;75(5):e20210104. https:\/\/doi.org\/10.1590\/0034-7167-2021-0104. PMID: 35584419.","journal-title":"Revista Brasileira de Enfermagem."},{"key":"4833_CR51","unstructured":"Philadelphia Department of Public Health. Division of HIV Health, Surveillance Report, 2022. Philadelphia, PA: 2023."},{"key":"4833_CR52","doi-asserted-by":"crossref","unstructured":"Forman E, Roth A, Huffaker S, Laurano R, Eger W, Akiba C, et al. The landscape of HIV services delivery in U.S. Syringe services programs: a qualitative exploration of current models and opportunities. In: The College on Problems of Drug Dependence 86th Annual Scientific Meeting; Montreal, Canada 2024.","DOI":"10.1016\/j.drugalcdep.2024.112150"},{"key":"4833_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04833-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:06:13Z","timestamp":1762175173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04833-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4833"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04833-5","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DK has conducted research on HIV prevention funded by grants from Gilead and Merck to his institution and has received personal fees for developing medical education content for Medscape, Virology Education, and UpToDate, Inc., and travel support from PrEP4All. TSB has conducted research on HIV prevention funded by grants from Gilead to his institution and has served as a consultant on grants from ViiV Healthcare. AMR, KMW, AG, SM, SB, KRA, AWC, and GI have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}